Physician profile
Denzel Pollock
NPI 1710951215
$1,086.40
in general payments reported to CMS, 2019-2025
14 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.69 · 2021: $78.20 · 2022: $12.51 · 2023: $47.67 · 2024: $340 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $248.79 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $240.64 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $100.71 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $90.41 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $84.58 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $68.00 | 2024-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.54 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $36.56 | 2021-2022 | |
| Tactile Systems Technology INC | $30.84 | 2025 | Nimbl, Flexitouch Plus |
| Abbott Laboratories | $28.31 | 2023 | Cardiomems |
| Kiniksa Pharmaceuticals International, Plc | $27.17 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $25.14 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $21.14 | 2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denzel Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.